From May 3 to 7, 2026, the ARVO Annual Meeting, one of the most authoritative and influential global ophthalmology events, was grandly held in Denver, the United States. The summit brought together top scientific researchers, clinicians, and renowned pharmaceutical enterprises worldwide. Focusing on the industrialization of cutting-edge ophthalmic technologies, innovative iteration of medical raw materials, and the transformation of clinical applications, participants jointly explored new development directions for the global eye health industry.

Topscience Biotech has long focused on the ophthalmology segment and accurately aligned with global eye health market demands. The company showcased its core products at the conference, including Pharmaceutical Grade Sodium Hyaluronate, Sterile Sodium Hyaluronate, and Medical Device Grade Sodium Chondroitin Sulfate Sodium. Among them, the high-end Pharmaceutical Grade Sodium hyaluronate series and Sterile Sodium Hyaluronate precisely meet the R&D requirements of various ophthalmic preparations. Covering a wide range of ophthalmic medical and preparation production scenarios, these products have garnered extensive attention across the industry.

•  Pharmaceutical Grade Sodium Hyaluronate

Topsience Biotech’s Pharmaceutical Grade Sodium Hyaluronate has completed API compliance registrations in multiple regions worldwide. The product contains ultra-low levels of nucleic acid and bacterial endotoxins, which are controlled at 0.01 (A260nm) and < 0.001 IU/mg respectively. With a molecular weight ranging from 100,000 to 3,000,000 Da, the product enables precise molecular weight regulation and supports personalized customization services. It is widely applicable to external ointments, eye drops, artificial tears, joint surgical fillers, and other products.

• Sterile Sodium Hyaluronate

Manufactured through a sterile filtration process, Topsience Biotech’s Sterile Sodium Hyaluronate requires no terminal sterilization and can be directly supplied to manufacturers of downstream sterile preparations and sterile medical devices. It is extensively adopted in high-end applications such as viscoelastic agents for intraocular implantation surgeries and fillers for joint surgeries.

Throughout the exhibition, Topsience Biotech’s booth maintained high popularity, attracting numerous new and existing clients as well as industry experts for on-site exchanges. Visiting clients held in-depth discussions with our sales team regarding core production processes, practical application solutions, customized specification requirements, global compliance qualifications and certifications, and other key topics. This event has laid a solid foundation for further in-depth overseas cooperation and global market expansion.

The successful conclusion of ARVO 2026 marks another important milestone in Topsience Biotech’s international development layout. Moving forward, the company will continue to deepen its footprint in the high-end pharmaceutical sector. Driven by technological innovation, Topsience Biotech will consistently empower the high-quality and sustainable development of the global eye health industry.